Clinical trials
Macular Degeneration clinical trials
Below are recruiting macular degeneration clinical trials, each written for real people, not researchers. We’re tracking 164 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06445322Recruiting
Finding people with Stargardt disease for ACDN-01
This prescreening study looks for people with a specific genetic eye condition called Stargardt disease to see if they might be able to join a future trial for a new treatment called ACDN-01.
San Francisco, CaliforniaAges 5 years+ - NCT06346600Recruiting
Long-term follow-up for SKG0106 in wet AMD
This study follows people who already received the SKG0106 injection in a previous trial for wet age-related macular degeneration (nAMD). It checks how they are doing over a longer period.
Boston, MassachusettsAges 50 years+ - NCT06271330Recruiting
Switching older injections to faricimab for wet AMD
This study looks at people with wet AMD who have been getting regular eye injections of either aflibercept or ranibizumab for over a year. The goal is to see what happens when they switch to a newer injection called faricimab.
Nantes, NantesAges 18 years+ - NCT05959005Recruiting
Tracking early macular atrophy changes in the eye
This study focuses on people age 50+ with early “wasting away” changes in the macula (central retina) called atrophic lesions. It aims to better understand how these early changes progress and how they affect vision testing, which may help improve future treatments.
Salt Lake City, UtahAges 50 years+ - NCT05932069Recruiting
Exercise program for intermediate age-related eye disease
This study tests whether an active (aerobic) exercise program can improve day-to-day function in Veterans with intermediate age-related macular degeneration (AMD). To join, you must have the right type stage of AMD, be able to do the assessments and exercise, and meet health and internet needs.
Decatur, GeorgiaAges 65–89 - NCT05913063Recruiting
Testing how the eye responds to tiny quantum states
This study looks at how the human eye detects very small “quantum” information. It compares people with certain vision conditions to people with normal vision to see how the eye’s macula and overall vision are involved.
Hong Kong, GuangdongAges 18 years+ - NCT05626114RecruitingPhase 2
Study of a lab-made eye treatment after subretinal surgery
This Phase 2 study tests OpRegen, a treatment delivered during special eye surgery, for geographic atrophy related to age-related macular degeneration (GA from AMD). It also includes an imaging “substudy” that uses detailed pictures of your retina to better track safety and activity.
Beverly Hills, CaliforniaAges 50 years+ - NCT05465252Recruiting
Omega-3 supplement to slow early dry macular degeneration
This trial studies whether taking omega-3 fatty acids can slow the worsening of dry age-related macular degeneration (AMD) in people with early or intermediate disease. It may help by testing if omega-3 changes how the retina changes over time.
ShanghaiAges 50–85 - NCT05210803Enrolling by invitationPhase 2
Long-term safety follow-up for wet AMD treatment
This study is a follow-up for people who have already received an injection of RGX-314 for wet age-related macular degeneration (AMD) in an earlier trial. It looks at how the treatment works over a longer time and any long-term effects.
Phoenix, ArizonaAges Any age - NCT04735263RecruitingPhase 2
Testing dark vision changes as a statin response signal
This Phase 2 study looks at whether changes in night/dark adaptation can show early whether high-dose atorvastatin (a statin) is helping intermediate age-related macular degeneration (AMD). If you fit, you may help researchers find an earlier way to tell who is responding.
Boston, MassachusettsAges 50–85 - NCT04697095Recruiting
Testing immune cells from specific AMD eye types
This study collects immune cells (from a blood sample) from people with certain types of age-related macular degeneration (AMD) and compares how long they live. It may help researchers understand how immune-related changes relate to AMD outcomes.
LyonAges 15 years+ - NCT04292080RecruitingPhase 2
Tecfidera trial to slow worsening geographic atrophy
This Phase 2 study tests dimethyl fumarate (Tecfidera) to slow the growth of geographic atrophy, a form of age-related macular degeneration that affects central vision. You may be asked to take the study medicine and attend regular eye scans over about 2 years to see if it helps.
Créteil, Val De MarneAges 55–85 - NCT04008121RecruitingEarly Phase 1
Testing an eye imaging drug during retinal blood-vessel photos
This early safety study tests how well and how safely an investigational dye (MB-102) works during a special eye imaging test of retinal and choroidal blood vessels. It compares it to the commonly used fluorescein dye and may help doctors refine future eye imaging approaches.
Ann Arbor, MichiganAges 18 years+ - NCT03848663Recruiting
Training with visual remapping to help reading with central vision loss
This study tests whether a computer-based visual training method (“remapping”) can help people read better even when they have reduced central vision. You may benefit if your eye condition is stable and your eyes can reliably track the training on an eye-tracker.
Minneapolis, MinnesotaAges 16 years+ - NCT03752840Recruiting
Community eye-worker program in Nepal
This trial tests a village-based approach to bring eye care closer to older community members. If you live in the right area and are willing to participate, it may help improve access to eye screening and services.
San Francisco, CaliforniaAges 60 years+ - NCT03683251RecruitingPhase 3
Extension study for a refillable eye implant plus ranibizumab
This trial studies whether continuing treatment with a refillable eye implant (Port Delivery System) and ranibizumab injection helps control a specific type of wet macular degeneration. It’s mainly for people who already finished an earlier related study and are able to keep up with frequent eye checks and procedures.
Phoenix, ArizonaAges 50 years+ - NCT02435940Recruiting
Registry for inherited eye vision conditions
This study is a registry, meaning it collects information about people with inherited retinal (retina) diseases. It may help researchers learn how these conditions progress and connect you with future studies or treatments.
Columbia, MarylandAges Any age - NCT01496625Recruiting
Biobank study for retinal diseases and comparison samples
This study collects and stores blood and eye-related medical information to help researchers better understand retinal diseases, including age-related macular degeneration and diabetic retinopathy. Your samples may also be used to compare people with retinal disease to people without it.
Bethesda, MarylandAges 2–120 - NCT01866371Recruiting
High-detail eye scans for children and adults
This study tests a high-resolution imaging method that takes very detailed pictures of the retina (the light-sensing layer at the back of the eye). You might benefit by getting your eye health checked in a structured imaging study—if you’re able to comfortably complete the scan.
Philadelphia, PennsylvaniaAges 7 years+ - NCT04129021Recruiting
Eye imaging test with fast detailed scans
This trial studies whether a new, very high-resolution and high-speed eye scan can be used for people with eye problems or for healthy volunteers. It may help doctors better “see” eye structures more clearly to guide care.
ParisAges 18 years+
Hear when a new Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for macular degeneration?
- Yes. Clin2 currently lists 164 recruiting macular degeneration studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a macular degeneration trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a macular degeneration trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Age-Related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Neovascular Age-Related Macular Degeneration (nAMD)
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- Neovascular (Wet) Age-Related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Exudative Age-Related Macular Degeneration
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.